Poor medication adherence in clinical trials: consequences and solutions
Poor adherence to medicines in clinical trials can undermine the value of the trials; for example, by compromising estimates of the benefits and risks of a medicine. In this article, we highlight such consequences and also discuss approaches to tackle this problem..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Nature reviews / Drug discovery - 16(2017), 3, Seite 149-150 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Breckenridge, Alasdair [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1038/nrd.2017.1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1993589619 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1993589619 | ||
| 003 | DE-627 | ||
| 005 | 20230518172624.0 | ||
| 007 | tu | ||
| 008 | 170512s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1038/nrd.2017.1 |2 doi | |
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC1993589619 | ||
| 035 | |a (DE-599)GBVOLC1993589619 | ||
| 035 | |a (PRQ)c1166-cd4715f028360ded29257b8fbed22607e4dda6a6a3302027befbdb30396dc4700 | ||
| 035 | |a (KEY)0473973620170000016000300149poormedicationadherenceinclinicaltrialsconsequence | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Breckenridge, Alasdair |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Poor medication adherence in clinical trials: consequences and solutions |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Poor adherence to medicines in clinical trials can undermine the value of the trials; for example, by compromising estimates of the benefits and risks of a medicine. In this article, we highlight such consequences and also discuss approaches to tackle this problem. | ||
| 700 | 1 | |a Aronson, Jeffrey K |4 oth | |
| 700 | 1 | |a Blaschke, Terrence F |4 oth | |
| 700 | 1 | |a Hartman, Dan |4 oth | |
| 700 | 1 | |a Peck, Carl C |4 oth | |
| 700 | 1 | |a Vrijens, Bernard |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nature reviews / Drug discovery |d London : Nature Publ. Group, 2001 |g 16(2017), 3, Seite 149-150 |w (DE-627)337806365 |w (DE-600)2062954-0 |w (DE-576)263021246 |x 1474-1776 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2017 |g number:3 |g pages:149-150 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1038/nrd.2017.1 |3 Volltext |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1872935610 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 16 |j 2017 |e 3 |h 149-150 | ||